RANDOMIZED DOUBLE BLIND STUDY TO EVALUATE BIOLOGIC ACTIVITY OF BG9273

这项研究是由克鲁格博士构思和设计的。然后，他获得了Biogen公司对他的项目的支持。Krueger博士设计了方案，生成了主要终点和次要终点，并确定了需要遵循的实验室参数。研究药物干扰t细胞的激活。该研究药物是CD2（一种t细胞共刺激信号）的可溶性配体，旨在阻断t细胞活化。可溶性配体是LFA-3蛋白（CD2配体）胞外结构域的克隆部分，它被设计成与人IgG1的CH2和CH3片段融合，作为增加血浆半衰期的手段。该药物耐受性良好，临床疗效明显。这项研究的结果正在准备发表。

This study was conceived and designed by Dr. Krueger. He then obtained support for his project from Biogen, Inc. Dr. Krueger designed the protocol, generated the primary end-points and the secondary endpoints, and determined the required laboratory parameters to be followed. The study drug interferes with T-cell activation. The study drug was a soluble ligand for CD2 (a T-cell co-stimulation signal) designed to block T-cell activation. The soluble ligand is a cloned portion of the LFA-3 protein (the CD2 ligand) extracellular domain, which was engineered to be fused with CH2 and CH3 segments of human IgG1 as a means of increasing plasma half-life. The drug was found to be well tolerated, and there was clear clinical evidence of efficacy. The results of this study are now in preparation for publication.